Oncology nurses play essential roles in the emerging field of cardio-oncology, which aims to protect patients’ heart function ...

Associate Health Minister with responsibility for Pharmac David Seymour, and Health Minister Simeon Brown welcome Pharmac’s ...

The article by Doshi et al entitled “Real-World Outcomes in Patients With Metastatic Renal Cell Carcinoma Treated With First-Line Nivolumab Plus Ipilimumab in the ...

Dr Aggarwal cited the example of cancer-treatment tablets such as Dasatinib, Lenalidomide, Nintedanib and Sunitinib that now cost around ₹4,000 a month. “However, imported drugs cost around ...

Such a head-to-head trial was conducted by GlaxoSmithKline to compare their tyrosine kinase inhibitor, pazopanib, to another tyrosine kinase inhibitor, sunitinib, in 1110 patients with metastatic ...

A subgroup analysis by the International Metastatic RCC Database Consortium (IMDC) risk showed PFS and objective response rates favored Cabometyx in combination with Opdivo versus sunitinib ...

Nivolumab plus cabozantinib significantly improved PFS, OS, and ORR compared with sunitinib in patients with advanced RCC. The combination therapy showed a median PFS of 16.4 months vs 8.3 months for ...

Correlates of immunotherapy response in metastatic clear cell renal cell carcinoma from circulating cell-free epigenomes. Association of baseline KIM-1 and KIM-1 change on treatment with outcomes.

Examined against the targeted cancer drug sunitinib, results saw the arm treated with combination therapy achieving a median OS of 46.5 months. Credit: Shutterstock / sasirin pamai. Five-year results ...

Platelet-derived growth factor receptor A (PDGFRA) mutations occur in approximately 10–15% of gastrointestinal stromal tumors (GISTs). These tumors with PDGFRA mutations have a different pathogenesis, ...